B-CPAP Cells

Unit

3 x 10^6 cells/ml

Cell Type

Tumor Cells

Tissue Type

Head-Neck cancer cell lines

Organism

Human

Donor History

Thyroid carcinoma

Growth Properties

Adherent

Growth Conditions

Culture medium: RPMI 1640

,

w: 2.0 mM stable Glutamine

,

w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% FBS. Dissociation reagent: Accutase. Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/B-CPAP-Cells/305081

SKU: 305081 Kategorie: ,
Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

B-CPAP is a human papillary thyroid carcinoma cell line that was established from the primary tumor of a 74-year-old woman. The cell line exhibits epithelial-like morphology and is commonly used in research to study thyroid cancer biology, including mechanisms of tumorigenesis and metastasis. B-CPAP cells are notable for harboring a BRAF V600E mutation, which is a common genetic alteration associated with aggressive thyroid cancers and serves as a critical model for evaluating BRAF inhibitors as therapeutic agents.

In addition to the BRAF mutation, B-CPAP cells express thyroid-specific markers such as thyroglobulin and thyroid-stimulating hormone receptor, making them a valuable model for studying thyroid gland function and pathology. They have been extensively used in studies investigating the signaling pathways involved in thyroid cancer progression, including MAPK/ERK pathway activation. These cells are also employed in drug resistance and apoptosis studies, providing insights into the mechanisms that might underpin therapeutic failures in thyroid cancer treatments.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.